Disclosure Plus

Exchange Issues Notice Designating RN2 Technologies Co., Ltd. as a Company with Inadequate Disclosure

Shin Ha-yeon
2026-07-24 17:36:46
[Edaily Reporter Shin Ha-yeon ] The KOSDAQ Market Division of the Korea Exchange announced on the 24th that RN2 Technologies Co., Ltd.(148250)has been notified of its impending designation as a company with inadequate disclosure due to a failure to disclose a correction to the resolution to convene a shareholders’ meeting in a timely manner.
The date on which the grounds for the disclosure arose was June 25. The Exchange plans to follow the relevant procedures and decide by August 19 whether to designate the company as a non-compliant discloser and determine the penalty points to be imposed.
RN2 Technologies Co., Ltd. currently has 0 penalty points imposed for non-compliant disclosures over the past year. If the company is ultimately designated as a non-compliant discloser and the penalty points imposed for this incident total 8 or more, trading in its shares may be suspended for one day. If the cumulative penalty points over the past year, including this incident, total 10 or more, the company may be subject to a substantive review of its listing eligibility.

Economy

Corporation

IT·Science

Economy

"AI Broadcasts on Its Own"... A Creator Startup Founded by a Former TikTok Employee [VC Cradle]

A virtual creator that doesn’t require a human actor has emerged. There is no pre-written script, nor is there an operator manipulating it in real time. Artificial intelligence (AI) hosts the broadcas…
2026-08-08 11:01:04

Corporation

Mezzion Pharma Co., Ltd. Simultaneously Improves Cysts and Kidney Function in ADPKD… “Moving Directly to Phase 2b Clinical Trials in Korea and the U.S.”

“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…
2026-08-08 08:16:01

IT·Science

SK BIOPHARMACEUTICALS Soars on Cenobamate Growth… The Era of 45% Generic Drug Prices Begins [Weekly Bio Roundup]

(Graphic: Generative AI) During the first week of August (August 3–7), SK BIOPHARMACEUTICALS posted its best-ever quarterly earnings, driven by the growth of its new epilepsy drug “cenobamate.” Ad…
2026-08-08 08:31:03